lasp1 antibody (Proteintech)
Proteintech is a verified supplier 
93
Structured Review
Proteintech
lasp1 antibody
Lasp1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 32 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lasp1/LASP1+Antibody/pmc12813356-62-62-65
Average 93 stars, based on 32 article reviews
Lasp1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 32 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lasp1/LASP1+Antibody/pmc12813356-62-62-65
Average 93 stars, based on 32 article reviews
lasp1 antibody - by Bioz Stars,
2026-09
93/100 stars
Images
1) Product Images from "Treating acute respiratory distress syndrome with a multifaceted nanomedicine: Inhibition of PANoptosis and enhancement of lung barrier integrity"
Article Title: Treating acute respiratory distress syndrome with a multifaceted nanomedicine: Inhibition of PANoptosis and enhancement of lung barrier integrity
Journal: Materials Today Bio
doi: 10.1016/j.mtbio.2025.102748
Figure Legend Snippet: (A) Schematic illustration depicting the involvement of PANoptosis in ALI/ARDS pathogenesis in mouse models and clinical samples. (B) Schematic representation of TPNs/Sal B synthesis. (C) Mechanistic diagram of TPNs/Sal B-mediated inhibition of various cell death pathways. (D) Schematic illustrating the role of TPNs/Sal B in maintaining lung epithelial barrier function through the regulation of LASP1. Created in BioRender. Cui, Y. (2026) https://BioRender.com/t11k604 .
Techniques Used: Inhibition
Figure Legend Snippet: TPNs/Sal B Improves Lung Epithelial Barrier Function in ALI Mice Through Upregulation of LASP1. (A) Plasma LASP1 levels in clinical ARDS patients compared to healthy controls (HC) (n = 16). (B) Plasma LASP1 levels in LPS-induced ALI mice (n = 8). (C) Plasma LASP1 levels in E protein-induced ALI mice (n = 8). (D) LASP1 protein levels in lung tissue from LPS or E protein-induced ALI mice (n = 6). (E) LASP1 mRNA levels in lung tissue from LPS-induced ALI mice (n = 8). (F) LASP1 mRNA levels in lung tissue from E protein-induced ALI mice (n = 8). (G–J) Correlation of Claudin-4 (G), Claudin-18 (H), Occludin (I), ZO-1 (J) with LASP1 protein expression (n = 30). Data are presented as mean ± SEM. Statistical significance was determined by t -test in A, by one-way ANOVA in B–F and by Pearson correlation analysis in G–J; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Techniques Used: Clinical Proteomics, Expressing
Related Articles
Control:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), RNA Sequencing:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Knockdown:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), ChIP-sequencing:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Expressing:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Quantitative RT-PCR:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), ChIP-qPCR:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Binding Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Luciferase:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Phospho-proteomics:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Incubation:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Marker:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Immunofluorescence:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Microscopy:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Transfection:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Immunoprecipitation:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Fractionation:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Co-Immunoprecipitation Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Western Blot:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Negative Control:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Purification:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Over Expression:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Ubiquitin Proteomics:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Cloning:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Mutagenesis:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Generated:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Pull Down Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Infection:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), CCK-8 Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Transwell Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Angiogenesis Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Migration:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Selection:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Xenograft Assay:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Sequencing:Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway. Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway Article Snippet: The antigen-antibody reaction was observed by enhanced chemiluminescence.The antigen-antibody reaction was observed by enhanced chemiluminescence.. The antibodies against the following proteins were used: Anti-NAT10 (ab194297, Abcam), NFE2L3 (A15761, ABclonal), HIF1 alpha (340462, ZENBIO), GAPDH (abs132004, Absin), Flag (F1804, Sigma), Article Title: LASP1 in the nucleus accumbens modulates methamphetamine-induced conditioned place preference in mice. Article Snippet: Abstract: Methamphetamine (METH) is a highly addictive and widely abused drug that causes complex adaptive changes in the brain’s reward system, such as the nucleus accumbens (NAc).. LASP1 (LIM and SH 3 domain protein 1) as an actin-binding protein, regulates synaptic plasticity.. However, the role and mechanism by which NAc LASP1 contributes to METH addiction remains unclear. Article Title: Inhibition of GLUD1 mediated by LASP1 and SYVN1 contributes to hepatitis B virus X protein-induced hepatocarcinogenesis Article Snippet: Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).Antibodies targeting mTOR, COXIV, and p-mTOR were obtained from AbClonal (Wuhan, China).. The antibodies against IL-32, SYVN1, AKT, PDK2, Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization. Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phosphoJAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phosphoERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization Article Snippet: The next day, after three times washing, membranes were incubated with secondary antibodies (diluted at 1:5000 with primary antibody dilution) at room temperature for 1 h. Immunoreactivities were determined using WesternBright ECL Western blotting detection kit (Advansta).. The following antibodies were used in this study: Vinculin (Proteintech, 26520-1-AP, 1:1000 dilution), CCDC137 (Proteintech, 27201–1-AP, 1:1000 dilution), JAK1 (Cell Signaling Technology, #3332, 1:1000 dilution), phospho-JAK1 (Cell Signaling Technology, #3331, 1:1000 dilution), STAT1 (Abcam, ab31369, 1:1000 dilution), phospho Y701-STAT1 (Abcam, ab30645, 1:1000 dilution), STAT3 (Cell Signaling Technology, #12640, 1:1000 dilution), phospho Tyr705-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), GSK3β (Cell Signaling Technology, #5676, 1:1000 dilution), phospho-GSK3β (Cell Signaling Technology, #5558, 1:1000 dilution), ERK (Cell Signaling Technology, #4695, 1:4000 dilution), phospho-ERK (Cell Signaling Technology, #4370, 1:4000 dilution), S6K (Cell Signaling Technology, #9262, 1:1000 dilution), phospho-S6K (Santa Cruz, sc-8418, 1:1000 dilution), S6 (Cell Signaling Technology, #2217, 1:2000 dilution), phospho-S6 (Cell Signaling Technology, #5364, 1:2000 dilution), JNK (Cell Signaling Technology, #9252, 1:2000 dilution), phospho-JNK (Cell Signaling Technology, #9251, 1:2000 dilution), YAP (Cell Signaling Technology, #14074, 1:1000 dilution), phospho-YAP (Cell Signaling Technology, #4911, 1:1000 dilution), AKT (Cell Signaling Technology, #4691, 1:1000 dilution), Ser473 phospho-AKT (Santa Cruz, sc-7985, 1:1000 dilution), Thr308 phospho-AKT (Cell Signaling Technology, #4056, 1:1000 dilution), Lamin A/C (Cell Signaling Technology, #2032, 1:1000 dilution), GFP (ABclonal, AE011, 1:4000 dilution), FOXM1 (Proteintech, 13147-1-AP, 1:1000 dilution), JTV1 (Proteintech, 10424-1-AP, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. Article Snippet: The sequence of siRNA and shRNA was provided in the Table S1.of siRNA and shRNA was provided in the Table S1. ... Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), Article Title: TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs Article Snippet: sequence of siRNA and shRNA was provided in the Table . .. Antibodies used as follows: Beta Actin (#66009-1-Ig, Proteintech, 1:5000 dilution), TRIM15 (#13623-1-AP, Proteintech, 1:1000 dilution), |
